Should Omnicell’s Shift Toward Software and Services Require Action From Omnicell (OMCL) Investors?

• Omnicell has recently accelerated its shift from hardware-focused sales toward software and services, including acquiring ANiGENT in October 2025 to broaden its drug diversion detection capabilities and recurring revenue base.
• This pivot toward subscription-like revenue streams is prompting investors to reassess Omnicell less as a traditional equipment maker and more as a healthcare IT provider, with different expectations for growth, risk and valuation.
• Next, we’ll examine how Omnicell’s push toward a software- and services-led model could reshape its existing investment narrative and risk profile.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.

Omnicell Investment Narrative Recap

To own Omnicell today, you need to believe its transition from hardware-heavy sales to a software and services model can eventually translate into healthier, more predictable earnings despite recent margin pressure. The ANiGENT acquisition fits this direction, enhancing Omnicell’s drug diversion detection tools and potentially reinforcing the key near term catalyst: growing recurring revenue. It does not, however, change the most immediate risk, which remains execution on this model shift while operating under cost and competitive pressures.

The ANiGENT deal, announced in October 2025, is especially relevant here because it directly expands Omnicell’s footprint in medication intelligence and compliance software, areas more aligned with healthcare IT valuations than traditional equipment multiples. As this acquisition is integrated, investors will likely watch whether it contributes meaningfully to subscription like revenue, which could help offset tariff related cost pressures and macro driven delays in large automation purchases over the next few quarters.

Yet, even as recurring revenue grows, investors should be aware that rising cybersecurity and compliance costs could...

Read the full narrative on Omnicell (it's free!)

Omnicell's narrative projects $1.3 billion revenue and $30.4 million earnings by 2028. This requires 3.0% yearly revenue growth and about a $7 million earnings increase from $23.1 million today.

Uncover how Omnicell's forecasts yield a $57.43 fair value, a 40% upside to its current price.

Exploring Other Perspectives

Some of the most cautious analysts were only expecting about 2.5% annual revenue growth and earnings of roughly US$35.4 million by 2028, so compared with concerns about rising cybersecurity and regulatory costs they paint a much more restrained picture of what Omnicell’s shift toward software and services might deliver, and the latest ANiGENT news could ultimately challenge or reinforce that view in ways worth examining.

Explore another fair value estimate on Omnicell - why the stock might be worth just $57.43!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Omnicell research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Omnicell research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Omnicell's overall financial health at a glance.

No Opportunity In Omnicell?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com